Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Raises $2.4M in Private Placement

NEW YORK (GenomeWeb) – Transgenomic said after the close of the market on Wednesday that it raised $2.375 million in gross proceeds from a private placement.

The financing was raised through a syndicate of new and existing institutional and other accredited investors, and funding will be used for general corporate and working capital purposes, including activities supporting Transgenomic's ICE COLD-PCR technology, the company said.

The company's common shares for the private placement were priced at $3.25 per share, which represents a 10 percent premium to Transgenomic's closing share price of $2.95 on Oct. 21. For each share of common stock purchased, the investors will receive a warrant to purchase .5 shares of the company's common stock at an exercise price of $4 per share. In the aggregate Transgenomic issued about 730,000 shares of its stock and 370,000 warrants, it said.

Earlier this year, the firm completed a financing that raised $7 million from affiliates of life sciences investment firm Third Security. Transgenomic's stock moved to the Nasdaq Capital Market in May.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.